Pharmacological or genetic activation of HO-1 significantly improves survival of many tumors, such as hepatomas, thyroid carcinomas, chronic myeloid leukemias, gastric carcinomas, and gliomas. The gene discussed is HMOX1; the disease is hepatocellular carcinoma.